Literature DB >> 26337038

Dysregulated ErbB4 Splicing in Schizophrenia: Selective Effects on Parvalbumin Expression.

Daniel W Chung1, David W Volk1, Dominique Arion1, Yun Zhang1, Allan R Sampson1, David A Lewis1.   

Abstract

OBJECTIVE: Alternative splicing of ErbB4 transcripts is dysregulated in the dorsolateral prefrontal cortex in schizophrenia. ErbB4 regulates the activity of parvalbumin interneurons, and therefore dysregulated ErbB4 splicing could contribute to lower parvalbumin interneuron activity and consequently lower parvalbumin levels in schizophrenia. However, ErbB4 is also present in calretinin interneurons, which are not affected in schizophrenia. Therefore, the authors hypothesized that dysregulated ErbB4 splicing occurs selectively in parvalbumin interneurons and is associated with lower parvalbumin levels in schizophrenia.
METHOD: Tissue samples enriched in calretinin and parvalbumin interneurons were laser microdissected from dorsolateral prefrontal cortex layers 2 and 4, respectively, from matched pairs of schizophrenia and comparison subjects. Transcript levels for pan-ErbB4, four ErbB4 splicing variants (JM-a, JM-b, CYT-1, CYT-2), parvalbumin, and calretinin were quantified by quantitative polymerase chain reaction (qPCR) in each layer. Transcript levels for myocardial infarction associated transcript (MIAT), which regulates ErbB4 splicing, were quantified in gray matter by qPCR and in parvalbumin interneurons by microarray.
RESULTS: Calretinin and parvalbumin mRNAs were preferentially expressed in layers 2 and 4, respectively. In schizophrenia subjects, lower parvalbumin levels, higher CYT-1 and JM-a levels, and lower CYT-2 and JM-b levels were detected selectively in layer 4. In layer 4, the JM-a/JM-b ratio was inversely correlated with parvalbumin levels in schizophrenia subjects. MIAT levels were preferentially higher in parvalbumin interneurons in schizophrenia subjects.
CONCLUSIONS: These findings suggest that elevated MIAT expression alters ErbB4 splicing selectively in parvalbumin interneurons in schizophrenia. Dysregulated ErbB4 splicing in schizophrenia may contribute to lower activity of parvalbumin interneurons and an activity-dependent down-regulation of parvalbumin expression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26337038      PMCID: PMC5242561          DOI: 10.1176/appi.ajp.2015.15020150

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  39 in total

1.  ErbB4 reduces synaptic GABAA currents independent of its receptor tyrosine kinase activity.

Authors:  Robert M Mitchell; Megan J Janssen; Irina Karavanova; Detlef Vullhorst; Katrina Furth; Anthony Makusky; Sanford P Markey; Andres Buonanno
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 2.  Function of ERBB4 is determined by alternative splicing.

Authors:  Ville Veikkolainen; Katri Vaparanta; Kalle Halkilahti; Kristiina Iljin; Maria Sundvall; Klaus Elenius
Journal:  Cell Cycle       Date:  2011-08-15       Impact factor: 4.534

3.  Elevated ErbB4 mRNA is related to interneuron deficit in prefrontal cortex in schizophrenia.

Authors:  Dipesh Joshi; Janice M Fullerton; Cynthia Shannon Weickert
Journal:  J Psychiatr Res       Date:  2014-03-03       Impact factor: 4.791

4.  Neuregulin 1 regulates excitability of fast-spiking neurons through Kv1.1 and acts in epilepsy.

Authors:  Ke-Xin Li; Ying-Mei Lu; Zheng-Hao Xu; Jing Zhang; Jun-Ming Zhu; Jian-Ming Zhang; Shu-Xia Cao; Xiao-Juan Chen; Zhong Chen; Jian-Hong Luo; Shumin Duan; Xiao-Ming Li
Journal:  Nat Neurosci       Date:  2011-12-11       Impact factor: 24.884

Review 5.  Neuregulin signaling, cortical circuitry development and schizophrenia.

Authors:  Beatriz Rico; Oscar Marín
Journal:  Curr Opin Genet Dev       Date:  2011-02-04       Impact factor: 5.578

6.  Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.

Authors:  T Hashimoto; D Arion; T Unger; J G Maldonado-Avilés; H M Morris; D W Volk; K Mirnics; D A Lewis
Journal:  Mol Psychiatry       Date:  2007-05-01       Impact factor: 15.992

7.  Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.

Authors:  Takanori Hashimoto; H Holly Bazmi; Karoly Mirnics; Qiang Wu; Allan R Sampson; David A Lewis
Journal:  Am J Psychiatry       Date:  2008-02-15       Impact factor: 18.112

Review 8.  Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases.

Authors:  Lin Mei; Klaus-Armin Nave
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

9.  Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia.

Authors:  David W Volk; Takurou Matsubara; Siyu Li; Elizabeth J Sengupta; Danko Georgiev; Yoshio Minabe; Allan Sampson; Takanori Hashimoto; David A Lewis
Journal:  Am J Psychiatry       Date:  2012-10       Impact factor: 18.112

10.  Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia.

Authors:  Nikolaos Mellios; Hsien-Sung Huang; Stephen P Baker; Marzena Galdzicka; Edward Ginns; Schahram Akbarian
Journal:  Biol Psychiatry       Date:  2009-01-01       Impact factor: 13.382

View more
  39 in total

1.  Developmental pruning of excitatory synaptic inputs to parvalbumin interneurons in monkey prefrontal cortex.

Authors:  Daniel W Chung; Zachary P Wills; Kenneth N Fish; David A Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-10       Impact factor: 11.205

2.  Markers of glutamate and GABA neurotransmission in the prefrontal cortex of schizophrenia subjects: Disease effects differ across anatomical levels of resolution.

Authors:  Samuel J Dienel; John F Enwright; Gil D Hoftman; David A Lewis
Journal:  Schizophr Res       Date:  2019-07-08       Impact factor: 4.939

3.  Ultrastructural analysis of parvalbumin synapses in human dorsolateral prefrontal cortex.

Authors:  Jill R Glausier; Rosalinda C Roberts; David A Lewis
Journal:  J Comp Neurol       Date:  2017-03-26       Impact factor: 3.215

4.  Temporal, Diagnostic, and Tissue-Specific Regulation of NRG3 Isoform Expression in Human Brain Development and Affective Disorders.

Authors:  Clare Paterson; Yanhong Wang; Thomas M Hyde; Daniel R Weinberger; Joel E Kleinman; Amanda J Law
Journal:  Am J Psychiatry       Date:  2016-10-24       Impact factor: 18.112

5.  Altered ErbB4 splicing and cortical parvalbumin interneuron dysfunction in schizophrenia and mood disorders.

Authors:  Daniel W Chung; Youjin Chung; H Holly Bazmi; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2018-08-02       Impact factor: 7.853

6.  Altered Gradients of Glutamate and Gamma-Aminobutyric Acid Transcripts in the Cortical Visuospatial Working Memory Network in Schizophrenia.

Authors:  Gil D Hoftman; Samuel J Dienel; Holly H Bazmi; Yun Zhang; Kehui Chen; David A Lewis
Journal:  Biol Psychiatry       Date:  2017-12-07       Impact factor: 13.382

7.  GABA and schizophrenia: Where we stand and where we need to go.

Authors:  Jill R Glausier; David A Lewis
Journal:  Schizophr Res       Date:  2017-02-05       Impact factor: 4.939

8.  Pathological Basis for Deficient Excitatory Drive to Cortical Parvalbumin Interneurons in Schizophrenia.

Authors:  Daniel W Chung; Kenneth N Fish; David A Lewis
Journal:  Am J Psychiatry       Date:  2016-07-22       Impact factor: 18.112

Review 9.  Layer 3 Excitatory and Inhibitory Circuitry in the Prefrontal Cortex: Developmental Trajectories and Alterations in Schizophrenia.

Authors:  Gil D Hoftman; Dibyadeep Datta; David A Lewis
Journal:  Biol Psychiatry       Date:  2016-06-04       Impact factor: 13.382

10.  Expression of Transcripts Selective for GABA Neuron Subpopulations across the Cortical Visuospatial Working Memory Network in the Healthy State and Schizophrenia.

Authors:  Makoto Tsubomoto; Rika Kawabata; Xiaonan Zhu; Yoshio Minabe; Kehui Chen; David A Lewis; Takanori Hashimoto
Journal:  Cereb Cortex       Date:  2019-07-22       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.